GU Cancers 2019 | Long-term benefits from hypoxia modification in bladder preservation: BCON trial update

Yee Pei Song, FCR, MBBCh, MRCP, of The Christie NHS Foundation Trust, Manchester, UK, gives an update from the Phase III BCON trial (NCT00033436), comparing the effect of radiotherapy alone with radiotherapy used in combination with hypoxia modifying agents, carbogen and nicotinamide, in bladder cancer. Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Song highlights the promising combined effects of radiotherapy and hypoxia modification on the overall survival of patients, and reports that these results are consistent with the fact that hypoxia is a poor prognostic factor in bladder cancer.